Where to Buy Micardis Plus 80: Vendor Comparison & Research Info

Micardis Plus 80 is a combination pharmaceutical formulation containing telmisartan and hydrochlorothiazide (HCTZ). It is primarily studied in cardiovascular and renal research involving the renin–angiotensin system, vascular resistance, sodium balance, and blood-pressure regulation.

Overview

Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the action of angiotensin II at the AT₁ receptor. Hydrochlorothiazide is a thiazide diuretic that influences renal sodium and water handling.

The combination provides a useful research model for investigating two complementary mechanisms involved in cardiovascular regulation: suppression of angiotensin II-mediated vasoconstriction and modulation of renal electrolyte and fluid balance.

Active Components

• Telmisartan: Angiotensin II AT₁ receptor antagonist

• Hydrochlorothiazide: Thiazide-type diuretic

• Therapeutic Class: ARB/diuretic combination

• Research Areas: Cardiovascular physiology, renal pharmacology, vascular biology, and electrolyte regulation

Mechanism of Action

Angiotensin II Receptor Blockade

Telmisartan selectively inhibits angiotensin II from activating AT₁ receptors. This pathway is involved in vasoconstriction, aldosterone signaling, sodium retention, and cardiovascular remodeling.

Renal Sodium Regulation

Hydrochlorothiazide acts primarily within the distal convoluted tubule of the nephron, where it inhibits sodium-chloride transport. This alters renal electrolyte and fluid handling and provides a model for studying diuretic-mediated changes in cardiovascular physiology.

Complementary Pharmacology

The two active components affect different regulatory systems. Telmisartan primarily targets the renin–angiotensin–aldosterone system, while hydrochlorothiazide modifies renal sodium and fluid balance.

Research Applications

Micardis Plus can be investigated in several scientific areas:

• Renin–Angiotensin System Research: Studying AT₁ receptor signaling and angiotensin II activity.

• Vascular Biology: Examining mechanisms involved in vascular tone and endothelial function.

• Renal Physiology: Investigating sodium, chloride, potassium, and water handling.

• Cardiovascular Research: Exploring relationships between vascular resistance, fluid balance, and cardiac workload.

• Electrolyte Research: Studying changes in renal electrolyte regulation associated with thiazide activity.

• Cardiovascular Remodeling: Investigating the role of angiotensin II signaling in structural changes within cardiovascular tissues.

Molecular Characteristics

Telmisartan

• Molecular Formula: C₃₃H₃₀N₄O₂

• Molecular Weight: 514.6 g/mol

• Chemical Class: Non-peptide angiotensin II receptor antagonist

Hydrochlorothiazide

• Molecular Formula: C₇H₈ClN₃O₄S₂

• Molecular Weight: 297.7 g/mol

• Chemical Class: Benzothiadiazine diuretic

Pharmacological Research

Research involving the combination may examine:

• AT₁ receptor occupancy and signaling

• Angiotensin II-mediated vasoconstriction

• Renal sodium transport

• Diuretic response

• Fluid-volume regulation

• Electrolyte homeostasis

• Vascular resistance

• Pharmacokinetic interactions between the active components

Analytical Testing

Quality assessment of combination formulations may include:

• High-Performance Liquid Chromatography (HPLC)

• Liquid Chromatography–Mass Spectrometry (LC-MS)

• Identity testing

• Assay determination

• Dissolution testing

• Stability analysis

• Content uniformity assessment

These analytical procedures help verify the identity, composition, stability, and consistency of the formulation.

Storage and Handling

Micardis Plus should be stored and handled according to the manufacturer's product documentation and applicable pharmaceutical or laboratory requirements. Researchers should consult the relevant Certificate of Analysis and formulation documentation when conducting experimental work.

Safety & Research Disclaimer

Micardis Plus contains pharmacologically active compounds that influence cardiovascular, renal, and electrolyte pathways. Research involving the formulation should be conducted by qualified personnel using appropriate laboratory and institutional procedures.

Micardis Plus 80 is intended for legitimate scientific, educational, or pharmaceutical research purposes and should not be used for self-treatment or unsupervised medication.